An observational study in Papillary Renal Cell Carcinoma, sponsored by AstraZeneca. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by AstraZeneca · Observational
This is a multi-center, observational, retrospective study designed to characterize the effectiveness and safety of sunitinib or sorafenib monotherapy in the treatment of Chinese adult patients with unresectable and locally advanced or metastatic PRCC, who have not received any prior systemic anticancer therapy in the metastatic setting. Electronic medical record (EMR) data of patients with 1L sunitinib or sorafenib monotherapy will be screened from Grade-A Tertiary hospitals in China. The study period is from 1st September 2007 to 31st December 2024.
This is a multi-center, observational, retrospective study designed to characterize the effectiveness and safety of sunitinib or sorafenib monotherapy in the treatment of Chinese adult patients with unresectable and locally advanced or metastatic PRCC, who have not received any prior systemic anticancer therapy in the metastatic setting.
Data will be screened and collected from Grade-A Tertiary hospitals in different provinces across China. Relevant patient-level information will be screened from EMR in multiple information systems in these hospitals. Information on baseline covariates, exposures and outcomes will be collected from hospital, including laboratory results, radiology and pathology reports, physician and nurse notes, prescriptions written and dispensed, surgical procedures, primary and subsequent diagnoses, and other details of a patient's outpatient visits and hospital admissions. Patients' information data will be collected and entered into the electronic data capture (EDC) system.
The study population consist of unresectable and locally advanced or metastatic PRCC patients in China who received 1L sunitinib or sorafenib between 1st September 2007 and 30th June 2024. Patients who were initially diagnosed with early stage PRCC and whose disease later progressed to unresectable and locally advanced or metastatic PRCC are eligible to be included in the study. Moreover, patients who relapsed after nephrectomy are also eligible to be included in the study.
1,965 studies on the registry are indexed under Carcinoma, Renal Cell; 378 are open to participants now.
This study's enrollment of 48 is below the median of 146 across 360 observational studies indexed under Carcinoma, Renal Cell.
Browse Carcinoma, Renal Cell studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
unresectable locally advanced or metastatic papillary renal cell carcinoma
Patients must meet all the following criteria to be included in the real-world cohort:
1)diagnosed with unresectable and locally advanced, or metastatic PRCC; 2)diagnosed with unresectable and locally advanced, or metastatic RCC, and with papillary (papillary ≥ 50%) as the dominant and presumed primary histology type.
3.Patients who received 1L therapy of sunitinib or sorafenib 4.Patients with tumor assessment or relevant clinical visit within 6-month follow-up since index date. (The rationale and details of 6-month minimal follow-up is presented in section 3.6). Death events within 6-month will be included.
Exclusion Criteria:
Patients who meet one or more following criteria will be excluded from the real-world cohort:
Patients who received systemic anti-cancer therapy for PRCC prior to the index date; The following is exception:
Prior systemic anti-cancer therapy in the neoadjuvant or adjuvant setting are acceptable if it was completed more than 12 months before metastatic/recurrent disease was diagnosed.
For patients who received prior systemic neoadjuvant/adjuvant therapies within 12 months before metastatic/recurrent disease was diagnosed, the neoadjuvant/adjuvant therapy will be counted as 1L therapy.
Patients are deemed eligible if the first therapy was only sustained for ≤ 3 days.
Other exclusion criteria revised according to study D5086C00001 (SAMETA) will also be applied, only if explicit evidence can be identified in the EMR data.
unresectable locally advanced or metastatic papillary renal cell carcinoma
Other: Observational, None intervention
Observational, None intervention
The primary objective is to characterize the real-world PFS (rwPFS) with either sunitinib or sorafenib.
The rwPFS is defined as time from the initiation of first dose of sunitinib or sorafenib until investigator-reported disease progression (assessed by physician's notes or radiology report), or death due to any cause (in the absence of progression), whichever occurred first.
Time frame: at least 6 months
The secondary objective is to characterize the rwPFS with sunitinib.
The rwPFS is defined as time from the initiation of first dose of sunitinib until investigator-reported disease progression (assessed by physician's notes or radiology report), or death due to any cause (in the absence of progression), whichever occurred first.
Time frame: at least 6 months
To characterize the OS with either sunitinib or sorafenib monotherapy
OS is defined as time from initiation of sunitinib or sorafenib until the date of death due to any cause.
Time frame: at least 6 months
To characterize the real-world ORR (rwORR) with either sunitinib or sorafenib monotherapy
The measure of interest is rwORR, defined as the proportion of participants who have reached CR or PR as determined by investigator-reported assessment.
Time frame: at least 6 months
To characterize the time-to-treatment discontinuation (TTD) with either sunitinib or sorafenib monotherapy
The TTD is defined as time from the date of initiation of sunitinib or sorafenib till their discontinuation due to any reasons or death.
Time frame: at least 6 months
To characterize the OS with sunitinib monotherapy.
OS is defined as time from initiation of sunitinib until the date of death due to any cause.
Time frame: at least 6 months
To characterize the rwORR with sunitinib monotherapy.
The measure of interest is rwORR, defined as the proportion of participants who have reached CR or PR as determined by investigator-reported assessment.
Time frame: at least 6 months
To characterize the TTD with sunitinib monotherapy.
The TTD is defined as time from the date of initiation of sunitinib till its discontinuation due to any reasons or death.
Time frame: at least 6 months
To characterize the rwPFS with sorafenib monotherapy.
The rwPFS is defined as time from the initiation of first dose of sorafenib until investigator-reported disease progression, or death due to any cause, whichever occurred first.
Time frame: at least 6 months
To characterize the OS with sorafenib monotherapy.
OS is defined as time from initiation of sorafenib until the date of death due to any cause.
Time frame: at least 6 months
To characterize the rwORR with sorafenib monotherapy.
The measure of interest is rwORR, defined as the proportion of participants who have reached CR or PR as determined by investigator-reported assessment.
Time frame: at least 6 months
To characterize the TTD with sorafenib monotherapy.
The TTD is defined as time from the date of initiation of sorafenib till its discontinuation due to any reasons or death.
Time frame: at least 6 months
To describe the adverse events (AEs) in Chinese patients of locally advanced or metastatic PRCC treated with either sunitinib or sorafenib monotherapy/ treated with sunitinib monotherapy/ treated with sorafenib monotherapy
AEs will be evaluated in terms of: Occurrence and frequency Seriousness AE with outcome of death AEs leading to discontinuation of sunitinib or sorafenib
Time frame: at least 6 months
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca